<DOC>
	<DOCNO>NCT02938793</DOCNO>
	<brief_summary>This investigator initiate single institution , open-label study evaluate antitumor activity , safety , tolerability durvalumab combination tremelimumab subject select advanced rare solid tumor .</brief_summary>
	<brief_title>Durvalumab Combination With Tremelimumab Subjects With Advanced Rare Solid Tumors</brief_title>
	<detailed_description>This investigator initiate single institution , open-label study evaluate antitumor activity , safety , tolerability durvalumab combination tremelimumab subject select advanced rare solid tumor . The dose-exploration phase , conduct across range tumor type , complete . The dose-expansion phase ongoing include certain soft tissue sarcoma , neuroendocrine tumor thymic carcinoma . Therefore , subject diagnose rare tumor exclude trial . Given safety tolerability data previous ongoing study ( Study D4190C00010 D4190C00006 ) , select dose evaluation subject enrol trial follow : Durvalumab , 1500 mg Q4W ( equivalent 20 mg/kg Q4W ) intravenously 13 dos Tremelimumab 75 mg Q4W ( equivalent 1 mg/kg Q4W ) intravenously 7 dos every 12 week 2 dos . Weight-based dose utilized patient &lt; 30 kg : durvalumab 20 mg/kg tremelimumab 1 mg/kg . Tremelimumab administer first infusion duration approximately 1 hour . The durvalumab infusion start approximately 1 hour end tremelimumab infusion infusion administer approximately 1 hour . The project Surveillance Rare Cancers Europe ( RARECARE ) collect data cancer 89 population-based cancer registries 21 European country , make possible study epidemiology cancer whole large heterogeneous population . Working database literature , RARECARE work group produce new list cancer develop new definition rare cancer ( incidence &lt; 6/100,000/year ) . This definition work list adopt rare tumor immunotherapy study .</detailed_description>
	<mesh_term>Rare Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Diagnosis rare advance solid malignancy meeting EORTC criterion . Subjects must fail ineligible receive standard treatment option available . Subjects must amenable biopsy tumor site recent ( &lt; 2 year ) archival material available . ECOG performance status 0 2 . Life expectancy &gt; 3 month . Adequate normal organ marrow function include : hemoglobin &gt; 9.0 g/dl ; ANC &gt; 1500 per mm3 ; platelet count &gt; 100,000 per mm3 ; bilirubin &lt; 1.5 x ULN ; ALT/AST &lt; 2.5 x ULN unless liver metastasis present case must &lt; 5 x ULN ; creatinine clearance &gt; 40 ml/min CockcroftGault 24 hour urine collection Previous treatment durvalumab tremelimumab . Prior treatment checkpoint inhibitor ( include antiCTLA4 , antiPD1 antiPDL1 ) . Rare malignancy investigation study include thymic carcinoma , certain sarcoma , neuroendocrine tumor . Untreated central nervous system metastatic disease . Active document autoimmune disease within previous 2 year . Uncontrolled psoriasis . Prior chemotherapy within 28 day first dose durvalumab tremelimumab . Steroid exposure within 28 day first dose durvalumab tremelimumab exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cancer , malignancy</keyword>
</DOC>